Nexalin item-level analysis of Alzheimer’s trial data flags sustained gains in memory and language domains
NXL•Post-hoc review points to sustained cognitive gains
Nexalin released a new post-hoc review of results from its previously published, sham-controlled Alzheimer’s device trial.
The analysis pointed to improvements in key cognitive functions, with benefits still seen months after treatment ended.
Findings are intended to shape endpoint choices and patient selection for a planned U.S. Alzheimer’s pilot study of its Gen-2 SYNC console.
Management framed the results as hypothesis-generating rather than definitive evidence of efficacy.
